免疫介导疾病治疗领导者Attovia Therapeutics成功登陆纳斯达克

美通社
Aug 06

上海2026年8月6日 /美通社/ -- 北京时间2026年8月5日,启明创投投资企业、免疫介导疾病治疗临床阶段生物制药公司Attovia Therapeutics(NASDAQ:ATTO)正式于纳斯达克上市。本次IPO发行价格17.00美元/股,开盘价21.00美元/股,市值约9.04亿美元。 Attovia于2023年正式开展运营,专注开发面向存在高度未满足临床需求的免疫介导疾病下一代生物治疗...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10